Supplement 4

2 GATHER compliance

- 3 This analysis complied with the Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER).¹
- 4 We have documented the steps in our analytical procedures and detailed the data sources used. The GATHER
- 5 recommendations can be found on the <u>GATHER website</u>.

| Item # | Checklist item | Reported on page # |
|----------|--|---|
| Objectiv | es and funding | - |
| 1 | Define the indicator(s), populations (including age, sex, and geographic entities), and time period(s) for which estimates were made. | Key Points Abstract Design Introduction paragraph 4 Methods |
| 2 | List the funding sources for the work. | All funding sources are listed in the Acknowledgments |
| Data Inp | uts | |
| For all | data inputs from multiple sources that are synthesized as part of the study: | |
| 3 | Describe how the data were identified and how the data were accessed. | Methods Input data eSection 3 Asymptomatic cases: Data eSection 3 Non-hospitalized cases: Proportion of deaths in long-term care |
| | | eSection 3 Hospitalized cases: Proportion deaths among hospitalized and ICU cases eSection 4 Data sources |
| 4 | Specify the inclusion and exclusion criteria. Identify all ad-hoc exclusions. | Methods Input data |
| | | eSection 3 Asymptomatic cases: Data eSection 3 Non-hospitalized cases: Proportion of deaths in long-term care eSection 3 Hospitalized cases: Proportion deaths among hospitalized and ICU cases eSection 4 Data sources |
| | | eFigure 8 PRISMA diagram |
| 5 | Provide information on all included data sources and their main characteristics. For each data source used, report reference information or contact name/institution, population represented, data collection method, year(s) of data collection, sex and age range, diagnostic criteria or measurement method, and sample size, as relevant. | Table 2, eTable 2 eSection 4 |

1

| | | Supplementary Appendix Data Inputs |
|----------|---|--|
| 6 | Identify and describe any categories of input data that have potentially important biases (e.g., based on characteristics listed in item 5). | Table 2 Discussion Limitations eSection 4 Data sources |
| For da | ta inputs that contribute to the analysis but were not synthesized as part of the study: | |
| 7 | Describe and give sources for any other data inputs. | Table 1 Disability weightseSection 4 Severity-weightedprevalence |
| For all | data inputs: | |
| 8 | Provide all data inputs in a file format from which data can be efficiently extracted (e.g., a spreadsheet rather than a PDF), including all relevant meta-data listed in item 5. For any data inputs that cannot be shared because of ethical or legal reasons, such as third-party ownership, provide a contact name or the name of the institution that retains the right to the data. | All input data are available in Supplementary Appendix Data Inputs |
| Data ana | llysis | |
| 9 | Provide a conceptual overview of the data analysis method. A diagram may be helpful. | Figure 1 conceptual framework of long COVID analysis eFigure 1 |
| | | eFigure 2 eFigure 7 |
| 10 | Provide a detailed description of all steps of the analysis, including mathematical formulae. This description should cover, as relevant, data cleaning, data pre-processing, data adjustments and weighting of data sources, and mathematical or statistical model(s). | Data cleaning, pre-processing, and adjustments: Methods eSection 3 Data subheadings eSection 4 Data sources, Data adjustments Models: Methods eSection 3 Methods subheadings eSection 4 Duration estimates eSection 4 Incidence and prevalence estimates eSection 4 Severity-weighted prevalence |

| 11 | Describe how candidate models were evaluated and how the final model(s) were | Models were pre-specified with |
|---------|--|---|
| | selected. | covariates and informative priors. |
| 12 | Provide the results of an evaluation of model performance, if done, as well as the results | eSection 4 Sensitivity analysis of |
| | of any relevant sensitivity analysis. | recovery pattern prior |
| 13 | Describe methods for calculating uncertainty of the estimates. State which sources of | Methods Incidence, prevalence, and |
| | uncertainty were, and were not, accounted for in the uncertainty analysis. | severity-weighted prevalence |
| | | eSection 4 Duration estimates |
| | | eSection 4 Incidence and prevalence |
| | | estimates |
| 14 | State how analytic or statistical source code used to generate estimates can be accessed. | Data and code used for analyses are |
| | | available in the upcoming GBD input data tool. Code is also available upor |
| | | request to swulf@uw.edu. Input data |
| | | are available as Appendix 2. |
| Results | and Discussion | ł |
| 15 | Provide published estimates in a file format from which data can be efficiently extracted. | Will be provided upon publication |
| 16 | Report a quantitative measure of the uncertainty of the estimates (e.g. uncertainty | Tables and in-text estimates include |
| | intervals). | uncertainty intervals. |
| 17 | Interpret results in light of existing evidence. If updating a previous set of estimates, | Discussion paragraphs 1-7 |
| | describe the reasons for changes in estimates. | |
| 18 | Discuss limitations of the estimates. Include a discussion of any modelling assumptions | Discussion Limitations |
| | or data limitations that affect interpretation of the estimates. | |

6

7 1. Stevens GA, Alkema L, Black RE, et al. Guidelines for Accurate and Transparent Health Estimates

8 Reporting: the GATHER statement. *PLOS Med*. 2016;13(6):e1002056.

9 doi:10.1371/journal.pmed.1002056

10